All links accessed October 2 2022

1. JP Manis. ‘Overview of therapeutic monoclonal antibodies’ UptToDate. Literature review current through: Sep 2022. Topic last updated March 14 2022. https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies
2. NICE. BNF. Drugs A to Z. https://bnf.nice.org.uk/drugs/
3. Y Wang. Monoclonal vs Polyclonal Antibody Drugs. Rapid Novor. September 8 2022. https://www.rapidnovor.com/monoclonal-vs-polyclonal-antibody-drugs/
4. eMC electronic medicines compendium. https://www.medicines.org.uk/emc
5. WHO. INN Working Doc. 21.531. New INN monoclonal antibody (mAb) nomenclature scheme. November 2021. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_-nomenclature-_2021.pdf
6. SS Guimaraes Kock et al. ‘International nonproprietary names for monoclonal antibodies: an evolving nomenclature system, mAbs’. Taylor & Francis Online. Article 2075078. Published online May 18 2022. 14:1. https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2075078
7. NIH National Cancer Isntitute. Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pd-1
8. H Yamane et al. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res. 2015. 5;4:1553–1557. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473331/
9. BL Salomon et al. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. Front. Immunol. Sec Immunological Tolerance and Regulation. March 12 2018. https://www.frontiersin.org/articles/10.3389/fimmu.2018.00444/full